Navigation Links
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors

ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.


Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.

Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.

"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months.  Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will accelerate Inhibikase's growth and entry into the clinic on a novel platform," said Milton H. Werner, Ph.D., Inhibikase Therapeutics' President and Chief Executive Officer. "The Board is comprised of four leaders in research, development and finance whose insights will be of tremendous value as we build an innovative company and a novel treatment approach for infectious disease."

About Inhibikase Therapeutics, Inc.Inhibikase Therapeutics is transforming the way pharmaceuticals attack infectious diseases.  Its small molecule platform enables treatment of bacterial AND viral infectious disease through a common mechanism of action.  The Company's host-targeting strategy using clinically validated drugs and targets treat disease with a low likelihood of stimulating resistance.  Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase Therapeutics is developing treatments for orphan indications arising from polyomaviruses, such as progressive multifocal leukoencephalopathy (PML),as well as a broad range of respiratory infectious diseases, including influenza, pneumonia and respiratory syncitial virus (RSV).Contact:  Milton H. Werner, Ph.D.President and Chief Executive OfficerInhibikase Therapeutics, Inc.(917) 494-0831

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... ... 2015 , ... Ministers, senior government and UN agencies, representatives ... of Excellence, and public R&D institutions, civil societies and other partners gathered today ... African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X Incorporated, ... explains what this means for business moving forward. , The Tri Lite heater business ... to sell personal heaters that reduce energy consumption, are economical and keep people warm ...
Breaking Medicine News(10 mins):